Feature pick to deliver sudden surge
| From Name: |
Rosalind |
| From Address: |
aeiekdrgifhoyapwo@prod-infinitum.com.mx |
| Date Received: |
02/07/2005 - 12:00:04 am |
| Spam Score: |
10.7 |
| Category: |
Investment |
View Spam Assassin Report :: Add/View Comments |
Email Preview:
Gqwespvfhe,Qykrtucke Bio-Matrix Scientific Gr0up, Inc.
Symbol: BMXG.PK Industry: Biotechnology; Stem Cell Technologies.
Current Price: .85 Shares Out.: 8.0 Million Est. Float: 2.5 Million
[...]
|
Email Message:
Return-Path:
Received: from prod-infinitum.com.mx (customer-201-133-170-242.prod-infinitum.com.mx [201.133.170.242] (may be forged))
by admin.domain.com (8.12.3/8.12.3/Debian-7.1) with ESMTP id j1759Opl003397
for ; Sun, 6 Feb 2005 23:09:40 -0600
Received: from [125.181.207.239] by mxs.perenter.com with ESMTP; Mon, 07 Feb 2005 01:09:19 +0400
Message-ID:
Date: Mon, 07 Feb 2005 07:42:59 -0300
Reply-To: "Rosalind"
From: "Rosalind"
User-Agent: Netscape6/6.1b1
MIME-Version: 1.0
To: "Suggs"
Subject: Feature pick to deliver sudden surge
Content-Type: text/plain;
charset="us-ascii"
Content-Transfer-Encoding: 7bit
Gqwespvfhe,Qykrtucke
Bio-Matrix Scientific Gr0up, Inc.
Symbol: BMXG.PK
Industry: Biotechnology; Stem Cell Technologies.
Current Price: .85
Shares Out.: 8.0 Million
Est. Float: 2.5 Million
Projected Valuation: 3.50 per shareBio-Matrix Scientific- Banking on Stem Cell Research.
BMXG is a stem cell-oriented biotechnology R&D firm, which is opening
two innovative AdultStem cell cryogenic banks. Cryobanks will provide
near-term revenue stream while BMXG develops new and innovative stem
cell technologies and products.The Stem Cell Revolution:
With breakthroughs in the late 1990's, stem cell research has been one
of the most exciting developments in biotechnology, promising to aid in
the treatment or cure of degenerative and chronic diseases, including
leukemia, cancer, and diabetes. Scientists say stem cells are the
future of medical science, offering potential cures to a host of diseases
and degenerative conditions. Market research firm, visiongain has
estimated that stem cell products will account for over 10 billion in
annual
sales by 2013- phenomenal growth for an industry which did not exist
only a few years ago. One of the most significant, near-term
commercialization opportunities for this research has been in the use of
stem
cells for bone marrow transplant. Increasingly, individuals are choosing
to store their own stem cells in cryogenic banks for future use in
fighting disease. A new industry of cord blood banks and specialized
transplant clinics has already risen to meet this demand, and successful
technology could meet the annual need for over 150,000 operations. Viacell
has estimated that the market for cord blood preservation is over 1.2
billion in the US, and 2 billion globally.
For our most recent Active Trader's profile, we have discovered a small
rapidly emerging company that is quickly becoming a major player in the
stem cell revolution, Bio-Matrix Scientific.About the Company: BMXG
Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an
innovative biotechnology R&D company, focused on the commercialization of
new
and groundbreaking stem cell technologies. The Company has focused its
initial efforts on the launch of an innovative AdultCryogenic stem cell
bank which will store stem cell tissues for use in treatment of future
diseases and ailments. The Company plans to launch its initial
cryogenic stem cell facilities in mid-2005, and is additionally exploring
opportunities for commercialization of new technologies in tissue
management, stem cell research instrumentation, and bio-systems monitoring.
With impending establishment of an AdultStem cell cryobank, research
efforts at the forefront of the stem cell market, and experienced
management
team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and
most dynamic player in the explosive stem cell research market.Investment Highlights:
BMXG is exceptionally well positioned at the forefront of one of the
most exciting new frontiers in biotech- stem cell research. While stem
cell therapy is still a new concept, expectations are high with research
firm visiongain estimating that stem cell product revenues will exceed
10 billion by 2013. Recently, California voters approved Proposition
71, a landmark piece of legislation that provides 3 billion in stem cell
funding over the next decade.
With its initial focus on the establishment of stem cell cryogenic stem
cell storage facilities, BMXG is well situated in a growing and
commercially successful market. There are more than 10 major cord blood
banks
in the world, preserving cells from more than 35,000 donors. Viacell
has estimated that this market is 1.2 billion in the US and over 2
billion worldwide. As the public understanding of stem cell benefits
improves, we expect this niche market to enjoy exponential growth. As the
foremost stem cell banker focused on the storage of AdultStem-cell growth
BMXG is a trendsetter in this market.
BMXG is making aggressive entry into the stem cell instrumentation
market with development of new medical devices specifically designed to
facilitate the removal and transplant of stem cells. The Company is in
the process of securing patent protection for its intellectual
properties, and we expect this to prove a major growth catalyst for BMXG
going
forward.
The Company benefits from a surprisingly strong (for a Pink Sheets
Company) and experienced management team, who have combined financial
acumen with scientific savvy to present a unique and promising model for
growth in the stem cell market. The Company's senior management team,
helmed by David Koos, PhD, has extensive experience in capital financing
and public company management, while its research efforts under Dr.
Philip Watts (PhD- Caltech) are involved in the newest academic research
into stem cell.Investment Conclusion: Projected Valuation: 3.50 per share
Wall Street has been quick to the react to the potential of stem cell
research and stem cell stocks are outperforming all of the major biotech
indices. Leading stem cell research companies such as StemCells, Inc.
(STEM), Aastrom Biosciences (ASTR), and Cryo-Cell (CCEL) have witnessed
average 52 week share price appreciation of over 230%! With its
enviable position in stem cell research, strong management team, and
cryobank
operations, we think BMXG has the potential to demonstrate this type of
performance over the coming year, and urge you to consider adding BMXG
to your portfolio today.Good Luck and Successful Trading.This publication is an independent publication with the goal of giving
investors the necessary knowledge to make rational and profitable
investment decisions. This publication does not provide an analysis of the
Companys financial position and is not an solicitation to purchase or
sell securities Investing in securities is speculative and carries risk.
It is advisable that any investment should be made after consulting
with your investment expert and after reviewing the financial statements
of the company. The information in this report is believed to be
reliable, but its accuracy cannot be assured. Past performance does not
insure
similar future results. This is not purported to be a complete and
thorough analysis of the featured company and reccomends a complete review
of the Company's regulatory filings at secgov The information herein
contains future looking statements and information within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, including statements regarding expected
continual growth of the featured company. Any statements that express or
involve discussions with respect to predictions, expectations, beliefs,
plans, projections, objectives, goals, assumptions or future events or
performance are not statements of historical fact and may be future
looking statements. Future looking statements are based on expectations,
estimates and projections at the time the statements are made that
involve a number of risks and uncertainties which could cause actual
results
or events to differ materially from those presently anticipated. Future
looking statements in this action may be identified through the use of
words such as projects, foresee, expects, will, anticipates, estimates,
believes, understands, or that by statements indicating certain actions
may, could, or might occur. The publisher discloses the receipt of six
thousand dollars from a third party, not an officer, director, or
affiliate shareholder of the company for the preparation of this online
report. Be aware of an inherent conflict of interest resulting from such
compensation due to the fact that this is a paid publication. All factual
information in this report was gathered from public sources, including
but not limited to Company Web sites, SEC filings and Company Press
Releases. This information is believed to be reliable but can make no
absolute certainty as to its accuracy or completeness. As with many
microcap stocks, todays company has additional risk factors worth noting.
Those factors may include an accumulated deficit since its inception, a
negative net worth, reliance on loans from officers, directors and a
majority shareholder to pay expenses, nominal cash and the need to raise
capital. The company may have a going concern opinion from its auditor.
Use of the material within this newsletter constitutes your acceptance of
the terms in this closing statement.
If you wish to stop future mailings, or if you feel you have been
wrongfully placed in our l i s t, please Go Here
(-stox0012@yahoo.com-)
Jnmylxvdmk,Enhiimie
|
Spam Assassin Report:
0.1 DATE_IN_FUTURE_03_06 Date: is 3 to 6 hours after Received: date
1.5 RAZOR2_CF_RANGE_51_100 BODY: Razor2 gives confidence level above 50%
[cf: 100]
0.1 RAZOR2_CHECK Listed in Razor2 (http://razor.sf.net/)
0.4 DNS_FROM_RFC_ABUSE RBL: Envelope sender in abuse.rfc-ignorant.org
2.8 RCVD_IN_DSBL RBL: Received via a relay in list.dsbl.org
[]
0.1 RCVD_IN_SORBS_DUL RBL: SORBS: sent directly from dynamic IP address
[201.133.170.242 listed in dnsbl.sorbs.net]
2.5 RCVD_IN_XBL RBL: Received via a relay in Spamhaus XBL
[201.133.170.242 listed in sbl-xbl.spamhaus.org]
1.8 RCVD_IN_BL_SPAMCOP_NET RBL: Received via a relay in bl.spamcop.net
[Blocked - see ]
1.4 DNS_FROM_RFC_POST RBL: Envelope sender in postmaster.rfc-ignorant.org
|
No Comments Posted Yet
Add your comment below! |
>> Add A Comment:
|
Spam Reg Home